PL3872091T3 - Przeciwciała przeciw sars-cov-2 - Google Patents
Przeciwciała przeciw sars-cov-2Info
- Publication number
- PL3872091T3 PL3872091T3 PL21159353.8T PL21159353T PL3872091T3 PL 3872091 T3 PL3872091 T3 PL 3872091T3 PL 21159353 T PL21159353 T PL 21159353T PL 3872091 T3 PL3872091 T3 PL 3872091T3
- Authority
- PL
- Poland
- Prior art keywords
- cov
- antibodies against
- against sars
- sars
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062981984P | 2020-02-26 | 2020-02-26 | |
| US202062982661P | 2020-02-27 | 2020-02-27 | |
| US202062987298P | 2020-03-09 | 2020-03-09 | |
| US202062989522P | 2020-03-13 | 2020-03-13 | |
| US202062990369P | 2020-03-16 | 2020-03-16 | |
| US202062992082P | 2020-03-19 | 2020-03-19 | |
| US202062994235P | 2020-03-24 | 2020-03-24 | |
| US202063001204P | 2020-03-27 | 2020-03-27 | |
| US202063003214P | 2020-03-31 | 2020-03-31 | |
| US202063005206P | 2020-04-03 | 2020-04-03 | |
| US202063010589P | 2020-04-15 | 2020-04-15 | |
| US202063011971P | 2020-04-17 | 2020-04-17 | |
| US202063014024P | 2020-04-22 | 2020-04-22 | |
| US202063023788P | 2020-05-12 | 2020-05-12 | |
| US202063025133P | 2020-05-14 | 2020-05-14 | |
| US202063039813P | 2020-06-16 | 2020-06-16 | |
| US202063043653P | 2020-06-24 | 2020-06-24 | |
| US202063050331P | 2020-07-10 | 2020-07-10 | |
| US202063052810P | 2020-07-16 | 2020-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3872091T3 true PL3872091T3 (pl) | 2023-12-27 |
Family
ID=74758682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21159353.8T PL3872091T3 (pl) | 2020-02-26 | 2021-02-25 | Przeciwciała przeciw sars-cov-2 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11168128B2 (pl) |
| EP (2) | EP4245373A3 (pl) |
| JP (2) | JP7275405B2 (pl) |
| KR (1) | KR20220164465A (pl) |
| AU (2) | AU2021227687B2 (pl) |
| BR (1) | BR112022017048A2 (pl) |
| CA (1) | CA3158752C (pl) |
| CL (1) | CL2022002335A1 (pl) |
| CO (1) | CO2022013525A2 (pl) |
| DK (1) | DK3872091T5 (pl) |
| ES (1) | ES2954629T3 (pl) |
| FI (1) | FI3872091T3 (pl) |
| HR (1) | HRP20231031T1 (pl) |
| HU (1) | HUE062777T2 (pl) |
| IL (1) | IL295801A (pl) |
| LT (1) | LT3872091T (pl) |
| MA (1) | MA56074B1 (pl) |
| MX (1) | MX2022010537A (pl) |
| PL (1) | PL3872091T3 (pl) |
| PT (1) | PT3872091T (pl) |
| RS (1) | RS64645B1 (pl) |
| SG (1) | SG11202110145SA (pl) |
| SI (1) | SI3872091T1 (pl) |
| SM (1) | SMT202300397T1 (pl) |
| TW (1) | TWI859420B (pl) |
| WO (1) | WO2021173753A1 (pl) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018138297A1 (en) | 2017-01-27 | 2018-08-02 | Kymab Limited | Anti-opg antibodies |
| MX2022011892A (es) * | 2020-03-26 | 2022-10-18 | Univ Vanderbilt | Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del sindrome respiratorio agudo grave (sars-cov-2). |
| SG11202103404PA (en) | 2020-04-02 | 2021-04-29 | Regeneron Pharma | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments |
| JP2023521418A (ja) | 2020-04-10 | 2023-05-24 | インビビド， インコーポレイテッド | コロナウイルスｓタンパク質に特異的な化合物及びその使用 |
| WO2021247779A1 (en) | 2020-06-03 | 2021-12-09 | Regeneron Pharmaceuticals, Inc. | METHODS FOR TREATING OR PREVENTING SARS-CoV-2 INFECTIONS AND COVID-19 WITH ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN ANTIBODIES |
| BR112022025229A2 (pt) * | 2020-06-12 | 2023-03-07 | Vir Biotechnology Inc | Terapias de anticorpos para infecção por sars-cov-2 |
| KR20230035350A (ko) | 2020-07-06 | 2023-03-13 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | SARS-CoV-2를 표적으로 하는 항원 결합 분자 |
| AU2021332340A1 (en) | 2020-08-26 | 2023-10-05 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting sars-cov-2 |
| WO2022054068A1 (en) * | 2020-09-14 | 2022-03-17 | Ramot At Tel-Aviv University Ltd. | Antibodies for the prevention, treatment and detection of coronavirus infection |
| CN116157685A (zh) * | 2020-09-22 | 2023-05-23 | 贝克顿·迪金森公司 | 用于检测样品中抗体的基于细胞的分析 |
| US11440952B2 (en) | 2020-10-16 | 2022-09-13 | Invisishield Technologies Ltd. | Compositions for preventing or treating viral and other microbial infections |
| US12109237B2 (en) * | 2020-12-15 | 2024-10-08 | Rutgers, The State University Of New Jersey | S309 chimeric antigen receptors and methods of use |
| WO2023001736A1 (en) | 2021-07-19 | 2023-01-26 | Universität Für Bodenkultur Wien | ENGINEERED ANTI-SARS COV-2 IgG3 ANTIBODIES |
| US20240400652A1 (en) * | 2021-09-01 | 2024-12-05 | Vir Biotechnology, Inc. | Antibody therapies for sars-cov-2 infection in pediatric subjects |
| WO2023034871A1 (en) * | 2021-09-01 | 2023-03-09 | Vir Biotechnology, Inc. | High concentration antibody therapies for sars-cov-2 infection |
| WO2023039442A1 (en) * | 2021-09-08 | 2023-03-16 | Vir Biotechnology, Inc. | Broadly neutralizing antibody combination therapies for sars-cov-2 infection |
| WO2023039540A2 (en) * | 2021-09-10 | 2023-03-16 | Jacobs Technion-Cornell Institute | Compositions and methods for determining humoral immune responses against seasonal coronaviruses and predicting efficiency of sars-cov-2 spike targeting, covid-19 disease severity, and providing interventions |
| EP4401832A1 (en) * | 2021-09-15 | 2024-07-24 | The Board of Trustees of the University of Illinois | Engineered receptors and monoclonal antibodies for coronaviruses and uses thereof |
| WO2023046057A1 (zh) * | 2021-09-24 | 2023-03-30 | 南京金斯瑞生物科技有限公司 | 抗SARS-CoV-2 L452R刺突蛋白的单克隆抗体及其应用 |
| US20250034234A1 (en) * | 2021-11-09 | 2025-01-30 | Rhode Island Hospital | Predicting covid-19 antibodies among survivors with deep rna sequencing |
| EP4433613A1 (en) | 2021-11-15 | 2024-09-25 | VIR Biotechnology, Inc. | Virological and molecular surrogates of response to sars-cov-2 neutralizing antibody sotrovimab |
| WO2023094980A1 (en) * | 2021-11-23 | 2023-06-01 | Fondazione Toscana Life Sciences | Antibodies to coronavirus |
| CN114107223B (zh) * | 2021-11-25 | 2024-03-26 | 湖北省疾病预防控制中心（湖北省预防医学科学院） | 利用TPCK胰酶提高SARS-CoV-2病毒细胞培养滴度的方法 |
| WO2023122211A2 (en) * | 2021-12-21 | 2023-06-29 | Duke University | Coronavirus antibodies and uses thereof |
| WO2023130123A2 (en) * | 2022-01-03 | 2023-07-06 | Twist Bioscience Corporation | Bispecific sars-cov-2 antibodies and methods of use |
| EP4460564A2 (en) * | 2022-01-08 | 2024-11-13 | Carogen Corporation | Multi-antigen therapeutic vaccines to treat or prevent chronic hepatitis b virus infection |
| CN116444656B (zh) * | 2022-01-10 | 2023-09-22 | 东莞市朋志生物科技有限公司 | 一种鉴别新冠突变型抗原的抗体、试剂及方法 |
| WO2023147251A1 (en) * | 2022-01-26 | 2023-08-03 | Academia Sinica | Antibody specific to coronaviruses and uses thereof |
| WO2023150307A2 (en) * | 2022-02-03 | 2023-08-10 | Abpro Corporation | Compositions and methods against a virus |
| TW202342510A (zh) | 2022-02-18 | 2023-11-01 | 英商Ｒｑ生物科技有限公司 | 抗體 |
| WO2023201256A1 (en) * | 2022-04-12 | 2023-10-19 | Vir Biotechnology, Inc. | High dose antibody therapies for sars-cov-2 infection |
| US11993644B2 (en) | 2022-05-06 | 2024-05-28 | Generate Biomedicines, Inc. | Antigen binding molecules targeting SARS-CoV-2 |
| WO2023224714A1 (en) * | 2022-05-16 | 2023-11-23 | Lawrence Livermore National Security, Llc | Repaired therapeutic and prophylactic antibodies against sars-cov-2 variants |
| KR20240008997A (ko) * | 2022-07-12 | 2024-01-22 | (재) 스크립스코리아항체연구원 | 사스-코로나 바이러스 2 중화 항체 |
| WO2024058987A2 (en) * | 2022-09-14 | 2024-03-21 | Merck Sharp & Dohme Llc | Polypeptides effective against multiple coronaviruses |
| WO2024102674A1 (en) | 2022-11-13 | 2024-05-16 | Generate Biomedicines, Inc. | Antigen binding molecules targeting sars-cov-2 |
| WO2024112818A1 (en) * | 2022-11-22 | 2024-05-30 | Humabs Biomed Sa | Engineered anti-sars-cov-2 antibodies and uses thereof |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2004024750A2 (en) | 2002-09-13 | 2004-03-25 | Dyax Corporation | Cd44-binding ligands |
| AU2004215125B2 (en) | 2003-02-26 | 2011-01-06 | Institute For Research In Biomedicine | Monoclonal antibody production by EBV transformation of B cells |
| AU2004228584A1 (en) | 2003-04-08 | 2004-10-21 | Coronovative B.V. | Severe acute respiratory syndrome (SARS) causing coronavirus |
| EP1644414B1 (en) | 2003-07-22 | 2015-01-14 | Crucell Holland B.V. | Binding molecules against sars-coronavirus and uses thereof |
| WO2005012360A2 (en) | 2003-07-22 | 2005-02-10 | Crucell Holland B.V. | Binding molecules against sars-coronavirus and uses thereof |
| WO2005047459A2 (en) | 2003-08-04 | 2005-05-26 | University Of Massachusetts | Sars nucleic acids, proteins, antibodies, and uses thereof |
| JP4620591B2 (ja) | 2003-09-24 | 2011-01-26 | 協和発酵キリン株式会社 | ヒトインスリン様成長因子に対する遺伝子組換え抗体 |
| WO2005060520A2 (en) | 2003-11-25 | 2005-07-07 | Dana-Farber Cancer Institute, Inc. | ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF |
| US7553944B2 (en) | 2004-07-21 | 2009-06-30 | The University Of Hong Kong | Human virus causing respiratory tract infection and uses thereof |
| ATE550037T1 (de) | 2004-11-11 | 2012-04-15 | Crucell Holland Bv | Zusammensetzungen gegen das sars-coronavirus und ihre verwendungen |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| MX2008014710A (es) | 2006-05-19 | 2009-02-12 | Amgen Inc | Anticuerpos para coronavirus del sars. |
| BRPI0714728A2 (pt) | 2006-08-04 | 2013-05-14 | Astrazeneca Ab | agente de ligaÇço alvejado, anticorpo, composiÇço, linhagem de cÉlula isolada molÉcula de Ácido nucleico isolada, vetor, cÉlula hospedeira, mÉtodos para produzir um agente de ligaÇço alvejado, para isolar um anticorpo ou porÇço de ligaÇço de antÍgeno do mesmo, para fabricar um anticorpo monoclonal humano, para tratar, prevenir ou aliviar os sintomas de um distérbio, para inibir a proliferaÇço de uma cÉlula cancerosa, para inibir uma atividade de erbb2 em uma cÉlula que expressa erbb2, e para modular uma atividade de erbb2 em uma cÉlula que expressa erbb2, e, animal transgÊnico nço humano ou planta transgÊnica |
| WO2008042814A2 (en) | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
| JP2010534057A (ja) | 2007-03-06 | 2010-11-04 | シムフォゲン・アクティーゼルスカブ | 呼吸器合胞体ウイルス感染症を治療するための組換え抗体 |
| WO2009128963A2 (en) | 2008-01-17 | 2009-10-22 | Humab, Llc | Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof |
| WO2009097133A2 (en) | 2008-01-30 | 2009-08-06 | Monsanto Technology, Llc | Transgenic plants with enhanced agronomic traits |
| EA034783B1 (ru) | 2009-03-20 | 2020-03-20 | Эмджен Инк. | Антитело-антагонист, специфичное для гетеродимера альфа4бета7 |
| US20120316071A1 (en) | 2009-11-04 | 2012-12-13 | Vaughn Smider | Methods for affinity maturation-based antibody optimization |
| EP2504364B1 (en) | 2009-11-24 | 2017-08-09 | Medimmune Limited | Targeted binding agents against b7-h1 |
| JO3274B1 (ar) | 2009-12-24 | 2018-09-16 | Regeneron Pharma | أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري |
| KR101299753B1 (ko) | 2010-11-19 | 2013-08-23 | 주식회사 단바이오텍 | 소 코로나바이러스 항원 결정기를 포함하는 스파이크 재조합 단백질 및 이에 대한 항체 |
| RS58141B1 (sr) | 2012-01-20 | 2019-02-28 | Genzyme Corp | Anti-cxcr3 antitela |
| AR090244A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Formulacion de anticuerpo anti-selectina p |
| CN104379734B (zh) | 2012-05-18 | 2018-05-15 | 诺维信公司 | 具有改进的转化效率的细菌突变体 |
| TWI641619B (zh) | 2012-06-25 | 2018-11-21 | 美商再生元醫藥公司 | 抗－ｅｇｆｒ抗體及其用途 |
| NZ720353A (en) | 2013-12-30 | 2019-12-20 | Epimab Biotherapeutics Inc | Fabs-in-tandem immunoglobulin and uses thereof |
| JO3701B1 (ar) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي |
| AR101669A1 (es) | 2014-07-31 | 2017-01-04 | Amgen Res (Munich) Gmbh | Constructos de anticuerpos para cdh19 y cd3 |
| WO2016073906A2 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related immunoassays |
| TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
| US10301377B2 (en) | 2015-02-24 | 2019-05-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use |
| IL304950A (en) | 2015-04-10 | 2023-10-01 | Amgen Inc | Interleukin for the expansion of myotonic control T-2 cells |
| MX2017014056A (es) | 2015-05-08 | 2018-04-10 | Eureka Therapeutics Inc | Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos. |
| WO2016181357A1 (en) | 2015-05-13 | 2016-11-17 | Zumutor Biologics, Inc. | Afucosylated protein, cell expressing said protein and associated methods |
| US10358497B2 (en) | 2015-09-29 | 2019-07-23 | Amgen Inc. | Methods of treating cardiovascular disease with an ASGR inhibitor |
| KR102398425B1 (ko) | 2016-03-08 | 2022-05-16 | 이나뜨 파르마 에스.에이. | Siglec 중화 항체 |
| WO2017220990A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 antibodies |
| US10759855B2 (en) | 2016-12-02 | 2020-09-01 | Rigel Pharmaceuticals, Inc. | Antigen binding molecules to TIGIT |
| WO2018112474A1 (en) | 2016-12-16 | 2018-06-21 | Merck Patent Gmbh | Methods for the use of galectin 3 binding protein detected in the urine for monitoring the severity and progression of lupus nephritis |
| WO2018138297A1 (en) | 2017-01-27 | 2018-08-02 | Kymab Limited | Anti-opg antibodies |
| EP3645562A1 (en) | 2017-06-28 | 2020-05-06 | Regeneron Pharmaceuticals, Inc. | Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof |
| WO2019024979A1 (en) | 2017-07-31 | 2019-02-07 | Institute For Research In Biomedicine | FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION |
| US11390686B2 (en) | 2017-08-09 | 2022-07-19 | University Of Saskatchewan | HER3 binding agents and uses thereof |
| KR101895228B1 (ko) | 2017-08-23 | 2018-10-30 | 대한민국 | 중동호흡기증후군 코로나바이러스의 스파이크 단백질에 대한 단일클론항체 및 이의 용도 |
| JP7387611B2 (ja) | 2017-09-22 | 2023-11-28 | ウーシー バイオロジクス アイルランド リミテッド | 新規二重特異性ポリペプチド複合体 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| SG11202103404PA (en) * | 2020-04-02 | 2021-04-29 | Regeneron Pharma | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments |
| WO2021203053A1 (en) * | 2020-04-03 | 2021-10-07 | Vir Biotechnology, Inc. | Immunotherapy targeting a conserved region in sars coronaviruses |
| CN116194476A (zh) * | 2020-04-14 | 2023-05-30 | 维尔生物科技有限公司 | 针对sars-cov-2的抗体和其使用方法 |
| CA3177169A1 (en) * | 2020-05-08 | 2021-11-11 | Vir Biotechnology, Inc. | Antibodies against sars-cov-2 |
| WO2021247925A1 (en) * | 2020-06-03 | 2021-12-09 | Vir Biotechnology, Inc. | Structure-guided immunotherapy against sars-cov-2 |
| BR112022025229A2 (pt) * | 2020-06-12 | 2023-03-07 | Vir Biotechnology Inc | Terapias de anticorpos para infecção por sars-cov-2 |
| CN112062859B (zh) | 2020-07-24 | 2022-08-09 | 沣潮医药科技（上海）有限公司 | 用于病原体清除的嵌合抗原受体及其应用 |
-
2021
- 2021-02-25 TW TW110106804A patent/TWI859420B/zh active
- 2021-02-25 SI SI202130058T patent/SI3872091T1/sl unknown
- 2021-02-25 EP EP23175785.7A patent/EP4245373A3/en active Pending
- 2021-02-25 EP EP21159353.8A patent/EP3872091B1/en active Active
- 2021-02-25 BR BR112022017048A patent/BR112022017048A2/pt unknown
- 2021-02-25 ES ES21159353T patent/ES2954629T3/es active Active
- 2021-02-25 AU AU2021227687A patent/AU2021227687B2/en active Active
- 2021-02-25 DK DK21159353.8T patent/DK3872091T5/da active
- 2021-02-25 PL PL21159353.8T patent/PL3872091T3/pl unknown
- 2021-02-25 PT PT211593538T patent/PT3872091T/pt unknown
- 2021-02-25 MX MX2022010537A patent/MX2022010537A/es unknown
- 2021-02-25 HR HRP20231031TT patent/HRP20231031T1/hr unknown
- 2021-02-25 KR KR1020227006804A patent/KR20220164465A/ko active IP Right Grant
- 2021-02-25 JP JP2022551302A patent/JP7275405B2/ja active Active
- 2021-02-25 HU HUE21159353A patent/HUE062777T2/hu unknown
- 2021-02-25 SG SG11202110145SA patent/SG11202110145SA/en unknown
- 2021-02-25 LT LTEP21159353.8T patent/LT3872091T/lt unknown
- 2021-02-25 SM SM20230397T patent/SMT202300397T1/it unknown
- 2021-02-25 CA CA3158752A patent/CA3158752C/en active Active
- 2021-02-25 WO PCT/US2021/019531 patent/WO2021173753A1/en active Application Filing
- 2021-02-25 MA MA56074A patent/MA56074B1/fr unknown
- 2021-02-25 US US17/185,340 patent/US11168128B2/en active Active
- 2021-02-25 FI FIEP21159353.8T patent/FI3872091T3/fi active
- 2021-02-25 RS RS20230783A patent/RS64645B1/sr unknown
- 2021-02-25 IL IL295801A patent/IL295801A/en unknown
- 2021-07-23 US US17/384,665 patent/US11479599B2/en active Active
-
2022
- 2022-08-26 CL CL2022002335A patent/CL2022002335A1/es unknown
- 2022-09-14 US US17/932,147 patent/US20230331821A1/en active Pending
- 2022-09-20 CO CONC2022/0013525A patent/CO2022013525A2/es unknown
- 2022-10-07 JP JP2022162148A patent/JP2023009046A/ja active Pending
-
2023
- 2023-05-22 AU AU2023203201A patent/AU2023203201A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3872091T3 (pl) | Przeciwciała przeciw sars-cov-2 | |
| IL289112A (en) | Antibodies against tigit | |
| IL291068A (en) | Anti-cd73 antibodies | |
| IL284584A (en) | Anti-tigit antibodies | |
| IL308741A (en) | Anti-SIRP-alpha antibodies | |
| GB2581174B (en) | Antibodies against hEPCR | |
| GB202105110D0 (en) | Anti-CD73 antibodies | |
| GB201905150D0 (en) | Ant-ige antibodies | |
| GB202014851D0 (en) | SARS-COV-2 antibodies | |
| LT4214240T (lt) | Anti-ccr8 antikūnai | |
| GB201900732D0 (en) | Antibodies | |
| GB201917480D0 (en) | Antibodies | |
| IL308100A (en) | Antibodies | |
| IL300142A (en) | Anti-IL13Ralpha2 antibodies | |
| IL299767A (en) | Antibodies against Alpha-4-Beta-7 | |
| IL289160A (en) | Anti-angpt2 antibodies | |
| GB202015115D0 (en) | ZIP12 Antibody | |
| GB2598698B (en) | Affinity-maturated anti-ASICIa antibodies | |
| GB202208773D0 (en) | Anti-SARS2-S antibodies | |
| IL308782A (en) | Antibodies | |
| IL307175A (en) | IL-38 specific antibodies | |
| GB202116709D0 (en) | Antibodies | |
| GB202115824D0 (en) | Antibodies | |
| GB202112297D0 (en) | Antibodies | |
| GB202111905D0 (en) | Antibodies |